Dataset from A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19

A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19

一项针对成人及12岁及以上儿童人群的II期随机、开放标签、多中心剂量探索研究，旨在评估AZD7442——由替沙格维单抗（Tixagevimab）与西加维单抗（Cilgavimab）组成的双单克隆抗体组合产品——用于新型冠状病毒肺炎（COVID-19）暴露前预防的安全性、免疫原性、药代动力学及药效动力学。